Bristol’s bad news is good for rivals: analysts
August 02, 2012 at 17:51 PM EDT
Bristol-Myers Squibb’s hepatitis C drug INX-189 might be a dud, but that may be a boon for rival drug developers, analysts say.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.